Table 1.

Stereotactic radiotherapy in prostate cancer.

Study	Treatment	# of patients	Risk group(s)	Median follow-up (months)	Late Grade 3 GU toxicity	Late Grade 3 GI toxicity	FFBF
Gantry-based systems
Madsen et al.52	33.5 Gy in 5 fx	40	Low	41	None	None	90% 4-years actuarial
Boike et al.53	45–50 Gy in 5 fx	45	Low and int	30, 18, 12	4%	2% plus 1 Grade 4	100%
Alongi et al.54	35 Gy in 5 fx	40	Low and int	11	None	None	–
Loblaw et al.56	35 Gy in 5 fx Once a week	84	Low	55	1%	None	98% 5-year
Cyberknife
King et al.45	36.25 Gy in 5 fx	69	Low	32	3.5%	None	97%
Friedland et al.40	35 Gy in 5 fx	112	Low, int, and high	24	< 1%	None	98%
Katz et al.43	35–36.25 Gy in 5 fx	304	Low, int and high	48	2%	None	97, 93, 75% 4-year actuarial
Freeman et al.47	7–7.25 Gy in 5 fx	41	Low	60	< 1%	None	93% 5-year actuarial
Bolzicco et al.42	35 Gy in 5 fx	100	Low, int and high	36	None	None	96%
McBride et al.51	36.25–37.5 Gy in 5 fx	45	Low	44	< 1%	None	100%
Ju et al.50	35–36.25 Gy in 5 fx	41	Int	21	None	None	97.56%
Chen et al.49	35–36.25 Gy in 5 fx	100	Low, int and high	26	None	None	99%
Kang et al.37	32–36 Gy in 4 fx	44	Low, int and high	40	None	None	100%, 100%, 90.9%
Oliai et al.48	37.5 Gy vs. 35–36.25 Gy in 5 fractions	70	Low, int and high	27–37	4%	None	100%, 95%, 77.1% 3-years
King et al.22	36.25 Gy in 4–5 fractions	1100	Low, int and high	36	–	–	93% 5-years

FFBF: free from biochemical failure; int.: intermediate; GU: genitourinary; GI: gastrointestinal.